國家衛生研究院 NHRI:Item 3990099045/10885
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 916581      Online Users : 1464
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10885


    Title: Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
    Authors: Yoshino, T;Arnold, D;Taniguchi, H;Pentheroudakis, G;Yamazaki, K;Xu, RH;Kim, TW;Ismail, F;Tan, IB;Yeh, KH;Grothey, A;Zhang, S;Ahn, JB;Chong, D;Chen, LT;Kopetz, S;Eguchi-Nakajima, T;Ebi, H;Ohtsu, A;Cervantes, A;Muro, K;Tabernero, J;Minami, H;Ciardiello, F;Douillard, JY
    Contributors: National Institute of Cancer Research
    Abstract: The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (CSCO), Korea (KACO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.
    Date: 2018-01
    Relation: Annals of Oncology. 2018 Jan;29(1):44-70.
    Link to: http://dx.doi.org/10.1093/annonc/mdx738
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000423741500013
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85041205697
    Appears in Collections:[Li-Tzong Chen] Periodical Articles

    Files in This Item:

    File SizeFormat
    PUB29155929.pdf1375KbAdobe PDF243View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback